Drug
delivery technologies provide commercial opportunities for
pharmaceutical companies by improving the chances of success for a
drug development project. They enable the formulation of a promising
molecule that might have poor solubility or require selective
delivery to a particular tissue, such as the brain. Similarly, drug
delivery technologies may enable companies to differentiate products
within crowded therapeutic areas, facilitate life cycle management
for existing drugs, and reposition existing drugs – proprietary or
generic – in new indications where the needs of the patient
population are different or, again, where more targeted delivery is
required. Products that are reformulated with novel drug delivery
systems do not meet the traditional criteria for innovative products
– in other words, products that include new active moieties.
Nevertheless, GBI Research’s analysis shows that the commercial
success of existing products that rely on innovative drug delivery
technologies is clear, and these products make significant positive
changes for patients.
Well, it can be
interesting...
No comments:
Post a Comment